在其实验性癌症药物早期试验结果显示出有希望的结果后,强度治疗公司的股票在2025年10月30日升了395%. Intensity Therapeutics' stock soared 395% on Oct. 30, 2025, after promising early trial results for its experimental cancer drug, which delivered chemotherapy directly to tumors.

在其实验性癌症治疗INT230-6的第1阶段试验结果为正确的结果之后,强度治疗 (INTS) 的股票在2025年10月30日升了395%.该试验直接将思丁和文布拉斯输入瘤. Intensity Therapeutics (INTS) shares surged 395% on October 30, 2025, following positive Phase 1/2 trial results for its experimental cancer therapy INT230-6, which delivered cisplatin and vinblastine directly into tumors. 发表在eBioMedicine上,数据显示75%的疾病控制率,软组织肉瘤患者的平均总生存期为11. 9个月和21. 3个月,其中一些患者经历了注射部位以外的瘤缩. Published in eBioMedicine, the data showed a 75% disease control rate, median overall survival of 11.9 months, and 21.3 months for soft-tissue sarcoma patients, with some experiencing tumor shrinkage beyond injected sites. 该公司筹集了超过1 100万美元的股本,将其现金跑道延长到2026年,并将2025年的Q2净损失减少了60%,从而增加了投资者的热情。 The company raised over $11 million in equity, extended its cash runway into 2026, and reduced its Q2 2025 net loss by 60%, contributing to investor enthusiasm. 在超过130美元的峰值之后,在下班后交易中股票下跌了31.9%至0.90美元,反映了盈利。 After a peak above $1.30, shares fell 31.9% to $0.90 in after-hours trading, reflecting profit-taking. 治疗仍处于早期发展阶段,没有宣布扩大试验或提交监管文件的计划。 The therapy remains in early development, with no announced plans for larger trials or regulatory submissions.